A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Somatropin (GENOTROPIN)

NORDITROPIN is a recombinant human growth hormone indicated for: • Pediatric : Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), sho....

First FDA approval1995-12-20
Generic availableNo (brand-only)
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$261.2M in CY2024 Part D spend44K claims · 8K beneficiaries · 329 plans surveyed

Lowest NADAC
$30.90/unit
10 NDCs benchmarked, lowest of all strengths.
Average NADAC
$739.98
Across all dosage forms in distribution.
Highest NADAC
$1810.40
Wide spread — brand-strength NDCs still in market.
Plans with PA
2604 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Somatropin used for?

NORDITROPIN is a recombinant human growth hormone indicated for: • Pediatric : Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), sho....

Is there a generic for Somatropin?

No. Somatropin is brand-only with no generic equivalents currently in market.

How much does my plan pay for Somatropin?

Across 329 Part D plans, Somatropin averages $739.98/unit (NADAC). Lowest available: $30.90/unit. Highest in distribution: $1810.40/unit.

Is Somatropin on the FDA shortage list?

Somatropin has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Recombinant Human Growth Hormone1 alternative in D1
01
Lonapegsomatropin-Tcgd
Brand: Skytrofa
Lowest NADAC
0Generic mfrs
$262,394CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.